You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CHG SCRUB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Chg Scrub patents expire, and what generic alternatives are available?

Chg Scrub is a drug marketed by Ecolab and is included in one NDA.

The generic ingredient in CHG SCRUB is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Chg Scrub

A generic version of CHG SCRUB was approved as chlorhexidine gluconate by BECTON DICKINSON on October 24th, 1989.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CHG SCRUB?
  • What are the global sales for CHG SCRUB?
  • What is Average Wholesale Price for CHG SCRUB?
Drug patent expirations by year for CHG SCRUB
Pharmacology for CHG SCRUB
Physiological EffectDecreased Cell Wall Integrity

US Patents and Regulatory Information for CHG SCRUB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ecolab CHG SCRUB chlorhexidine gluconate SOLUTION;TOPICAL 019258-002 Jul 22, 1986 OTC No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

CHG SCRUB Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Chlorhexidine Gluconate (CHG) Wipes and Cloths

Introduction

Chlorhexidine gluconate (CHG) wipes and cloths have become essential tools in the prevention of healthcare-associated infections (HAIs) and surgical site infections (SSIs). Here, we delve into the market dynamics and financial trajectory of these products, highlighting key drivers, restraints, and future projections.

Market Size and Growth

The global CHG wipes market is experiencing robust growth. In 2023, the market size was valued at $47.4 billion and is expected to grow to $49.92 billion in 2024, with a compound annual growth rate (CAGR) of 5.3%[1].

By 2028, the market is projected to reach $61.46 billion, driven by factors such as pandemic-driven hygiene measures, a growing elderly population, global expansion of healthcare facilities, and increased consumer awareness and demand for infection control products[1].

Segmentation by Type

The CHG wipes market is segmented into two main types:

  • CHG Bath Wipes: These are used for patient bathing and are particularly effective in reducing the risk of infections.
  • CHG Alcohol-Based Wipes: These combine the antimicrobial properties of CHG with the rapid action of alcohol, making them ideal for preoperative skin preparation and hand hygiene[1].

Segmentation by Application

CHG wipes are used across various applications, including:

  • Surgical Site Infections: To reduce the risk of SSIs, especially in procedures like total knee and hip arthroplasties.
  • Central Line-Associated Bloodstream Infections: To prevent infections related to central lines.
  • Catheter-Associated Urinary Tract Infections: To reduce the risk of UTIs in patients with catheters.
  • Other Applications: Including general skin cleansing and wound care[1].

Segmentation by Distribution Channel

The distribution channels for CHG wipes include:

  • Pharmacies
  • Supermarkets
  • Specialty Stores
  • Direct Sales Each channel plays a significant role in making these products accessible to various end-users[1].

Segmentation by End User

The primary end-users of CHG wipes are:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Other End-Users These institutions rely heavily on CHG wipes for infection control and patient safety[1].

Drivers of the Market

Several factors drive the growth of the CHG wipes market:

  • Healthcare-Associated Infections (HAIs) Concerns: The increasing awareness and efforts to reduce HAIs have boosted the demand for CHG wipes.
  • Surgical Site Infections Prevention: The effectiveness of CHG in reducing SSIs has made it a staple in preoperative and postoperative care.
  • Regulatory Endorsement: Regulatory bodies have endorsed the use of CHG wipes, further driving their adoption.
  • Increased Hospital Admissions: Rising hospital admissions due to various health conditions have increased the demand for infection control products[1].

Restraints of the Market

Despite the growth, there are some restraints:

  • High Inflation: Economic instability and high inflation can affect the purchasing power of healthcare institutions and consumers.
  • Ukraine-Russia War Impact: Global conflicts can disrupt supply chains and affect market stability.
  • COVID-19 Impact: While COVID-19 has increased hygiene awareness, it has also posed challenges in terms of supply chain disruptions and economic instability[1].

Financial Projections

The financial trajectory of the CHG wipes market is promising:

  • By 2028, the market is expected to reach $61.46 billion, growing at a CAGR of 5.3%[1].
  • For CHG cloths specifically, the market size is projected to reach $15.46 billion by 2031, growing at a CAGR of 3.2% from 2024-2031[4].

Regional Market Dynamics

The market dynamics vary by region:

  • North America: Driven by stringent healthcare protocols and high awareness of infection control, this region sees significant adoption in hospitals and surgical centers[4].
  • Europe: Benefits from advanced healthcare infrastructure but faces strict regulatory frameworks governing antiseptic products[4].
  • Asia-Pacific: Rapid market growth is propelled by rising healthcare investments and increasing awareness of HAIs. Countries like China and India are key drivers[4].
  • Middle East and Africa: Growing market with improving healthcare facilities, but faces challenges due to socio-economic disparities and limited healthcare infrastructure[4].
  • Latin America: Gradual market expansion driven by increased governmental healthcare spending, though economic instability and varied healthcare standards pose hurdles[4].

Economic Impact

The use of CHG cloths has a significant economic impact:

  • Studies have shown that using CHG cloths can result in substantial cost savings by reducing infection rates. For example, a study found that using CHG cloths could result in a net savings of approximately $2.1 million per 1,000 total knee arthroplasty patients[5].

Clinical Efficacy

Clinical studies underscore the efficacy of CHG products:

  • A 4% CHG solution like Hibiclens has been shown to reduce facility infection rates significantly. It reduces C. difficile infections by 70%, primary bloodstream infections by 61%, MRSA by 32%, and VRE by 50%[2].
  • CHG cloths have been found to decrease bacterial counts and reduce the incidence of periprosthetic infections in surgical patients[5].

Future Trends

Several trends are expected to shape the market in the future:

  • Environmentally Friendly Formulations: There is a growing demand for eco-friendly products, which is likely to influence the development of CHG wipes and cloths.
  • Enhanced Packaging Designs: Innovations in packaging to improve usability and compliance are anticipated.
  • Innovation in Wipe Textures: New textures that enhance user comfort and effectiveness are being developed.
  • Telemedicine and Remote Care: The rise of telemedicine may influence how CHG products are used and distributed.
  • Focus on OTC and Retail Market: There is an increasing focus on making CHG products available over-the-counter and through retail channels[1].

Key Takeaways

  • The CHG wipes and cloths market is driven by concerns over HAIs, SSIs, and regulatory endorsements.
  • The market is expected to grow significantly, reaching $61.46 billion by 2028 for CHG wipes and $15.46 billion by 2031 for CHG cloths.
  • Regional dynamics vary, with North America and Europe leading in terms of adoption, while Asia-Pacific shows rapid growth.
  • Clinical studies highlight the efficacy of CHG products in reducing infection rates and associated costs.
  • Future trends include environmentally friendly formulations, enhanced packaging, and a focus on OTC and retail markets.

FAQs

Q: What are the primary types of CHG wipes? A: The primary types are CHG Bath Wipes and CHG Alcohol-Based Wipes[1].

Q: How effective are CHG cloths in reducing surgical site infections? A: Studies have shown that CHG cloths can significantly reduce the incidence of SSIs, with some studies indicating a reduction from 1.9% to 0.03% in periprosthetic infections[5].

Q: What are the key drivers of the CHG wipes market? A: Key drivers include concerns over HAIs, prevention of SSIs, regulatory endorsements, increased hospital admissions, and the rise in chronic diseases[1].

Q: What is the projected market size for CHG cloths by 2031? A: The market size for CHG cloths is projected to reach $15.46 billion by 2031, growing at a CAGR of 3.2% from 2024-2031[4].

Q: How do regional market dynamics influence the adoption of CHG products? A: Regional dynamics such as stringent healthcare protocols in North America, advanced healthcare infrastructure in Europe, and rising healthcare investments in Asia-Pacific significantly influence the adoption and growth of CHG products[4].

Sources

  1. The Business Research Company: Global Chlorhexidine Gluconate (CHG) Wipes Market Report 2024.
  2. Infection Control Products: Surgical Scrub Hibiclens 4% Strength CHG (Chlorhexidine Gluconate).
  3. Market Research Future: Chlorhexidine Gluconate Cloth Market.
  4. Verified Market Research: Chlorhexidine Gluconate CHG Cloth Market Size, Share & Forecast.
  5. Stryker: The Utility of Chlorhexidine Cloth Use for the Prevention of Surgical Site Infections.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.